Aion Therapeutic Inc.
AION
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 117.46% | 179.97% | 168.33% | 104.60% | 44.15% |
| Depreciation & Amortization | -- | -- | 19,900.00% | 158.14% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.70% | 342.62% | 270.85% | 136.54% | 39.77% |
| Operating Income | -88.24% | -80.79% | -184.54% | -20.35% | -39.77% |
| Income Before Tax | -219.46% | -9.95% | -2,482.09% | -74.94% | -41.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -219.46% | -9.95% | -2,482.09% | -74.94% | -41.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.46% | -9.95% | -2,482.09% | -74.94% | -41.53% |
| EBIT | -88.24% | -80.79% | -184.54% | -20.35% | -39.77% |
| EBITDA | -- | -- | -178.97% | -23.63% | -- |
| EPS Basic | -28.57% | 64.71% | -880.00% | 18.18% | -16.67% |
| Normalized Basic EPS | -50.00% | 60.00% | 14.29% | 45.45% | 0.00% |
| EPS Diluted | -28.57% | 64.71% | -880.00% | 18.18% | 12.50% |
| Normalized Diluted EPS | -50.00% | 60.00% | 14.29% | 45.45% | 0.00% |
| Average Basic Shares Outstanding | 154.32% | 207.07% | 176.21% | 114.46% | 29.21% |
| Average Diluted Shares Outstanding | 154.32% | 207.07% | 176.21% | 114.46% | 29.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
